Karnataka Urges Centre to Extend 30% Trade‑Margin Cap Beyond Cancer Drugs to Cardiac & Kidney Medicines

Key Insight

Karnataka pushes for 30% price cap on cardiac and kidney drugs to curb patient costs

Key Facts

1. The Karnataka health ministry wrote to the Union seeking to extend NPPA’s 30% trade‑margin cap beyond anti‑cancer drugs.
2. NPPA (National Pharmaceutical Pricing Authority) is a statutory body under the Ministry of Commerce that regulates drug prices.
3. The 30% cap currently applies to non‑scheduled medicines – high‑cost, newer drugs not covered under the scheduled price‑control list.
4. Karnataka wants the cap to include life‑saving cardiac and kidney medicines to reduce out‑of‑pocket expenditure.
5. An expert committee under the Directorate General of Health Services (DGHS) will examine the feasibility of the extension.

Background

Price control of essential medicines falls under the health‑care governance domain and tests the fiscal responsibilities of both centre and states. Extending the cap aligns with the goal of affordable health care and raises questions about federal cooperation and regulatory authority under the Constitution.

UPSC Syllabus

• GS2 — Functions and responsibilities of Union and States
• Prelims_GS — Constitution and Political System
• Essay — Democracy, Governance and Public Administration
• Essay — Economy, Development and Inequality
• Essay — Youth, Health and Welfare
• GS2 — Government policies and interventions for development

Mains Angle

GS‑2: Discuss the challenges and implications of extending price‑control measures on high‑cost medicines. A possible question could ask about the role of centre‑state coordination in ensuring affordable health care.